2 completed, 1 active not recruiting, 1 terminated, 1 unknown. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Cantex Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azeliragon in MGMT Unmethylated Glioblastoma Azeliragon - Glioblastoma | Phase 2 | Active not recruiting | Cantex Pharmaceuticals | 30 | 2023-09-12 | 2026-03-31 |
| Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg - Glioblastoma | Phase 1 / Phase 2 | Completed | Cantex Pharmaceuticals | 33 | 2023-09-05 | 2026-10-19 |
| Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer Azeliragon - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Cantex Pharmaceuticals | 30 | 2023-06-01 | 2024-06-14 |
| Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine Safety Laboratories, AE Assessment, Physical Exam - Metastatic Pancreatic Cancer | Phase 2 | Terminated | HonorHealth Research Institute | 1 | 2019-10-17 | 2023-10-18 |
| Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma Disulfiram/Copper, Temozolomide (TMZ) - Recurrent Glioblastoma | Phase 2 | Completed | Cantex Pharmaceuticals | 23 | 2017-03-09 | 2021-09-13 |
Glioblastoma (3) · Pancreatic Neoplasms (2)
azeliragon (3) · 130-nm albumin-bound paclitaxel (1) · Clinical Protocols (1) · Disulfiram (1) · Gemcitabine (1) · Gluconates (1) · Restraint, Physical (1) · Temozolomide (1) · disulfiram-copper (1)
United States (4) · Spain (1)
Andrew Hendifar, MD (1) · Gayle Jameson, ACNP-BC (1) · Jiayi Huang, MD (1) · Stephen G Marcus, MD (1)